Not Signed In -
Haloperidol Tablets |
Haldol Tablets |
Clinical Trial: Study Comparing Olanzapine with Haloperidol for the Relief of Nausea and Vomitting in Patients with Advanced Cancer
This study is currently recruiting patients.
Verified by Alberta Cancer Board July 2005
Purpose
To compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line aritemetic therapy.
| Condition | Intervention | Phase |
|---|---|---|
| Refractory Nausea | Drug: olazapine/haldol | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized Double-Blind, Parallel Group Study Domparing Olanzapine (Zyprexa) with Haloperidol (Novo-Periodol) for the Relief of Nausea and Vomitting in Patients with Advanced Cancer
Further Study Details:
Primary Outcomes: Severity of nausea on day 3 and 5
Expected Total Enrollment: 80
Expected Total Enrollment: 80
Study start: May 2005; Expected completion: May 2009
Last follow-up: May 2008; Data entry closure: May 2009
To compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line aritemetic therapy
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- >18 years signficant nausea/vomitting failed maxeran and domperidone underlying treatment of causes has failed adequate cognitive function communicates well
Exclusion Criteria:
- partial/complete bowel obstruction currently taking haldol or olanzapene has drug induced extra pyramidal symptoms parkinson''''s disease undergoing chemo or RT to brain, abdomen, stomach or esophagus
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00124930
Carla Stiles 403-210-8423 carla.stiles@calgaryhealthregion.ca
Canada, Alberta
Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada; Recruiting
Rachel Syme, Ph.D. 403-521-3388 clinical_trials_tbcc@cancerboard.ab.ca
Study chairs or principal investigators
Jose Pereira, Principal Investigator, Alberta Cancerboard
More Information
Study ID Numbers: 18731; MCT 71119
Last Updated: August 1, 2005
Record first received: July 29, 2005
ClinicalTrials.gov Identifier: NCT00124930
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-02
Last Updated: August 1, 2005
Record first received: July 29, 2005
ClinicalTrials.gov Identifier: NCT00124930
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-02
Resources
- Haldol Tablets (Drug Digest)
- Haloperidol Tablets (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
